

optimi™ CSE: OPTI | OTCQX: OPTHF | FRA: 8BN

SUBSCRIBE FOR UPDATES





BACK TO NEWS

OPTIMI HEALTH ACQUIRES EXTENSIVE CATALOG OF PSYCHEDELIC AND FUNCTIONAL MUSHROOM GENETICS

MAY 17, 2022 | CORPORATE NEWS

New strains to provide crucial insights in mental health research across the sector

VANCOUVER, British Columbia, May 17, 2022 (GLOBE NEWSWIRE) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has completed the acquisition of a diverse catalog of psilocybin and functional mushroom strains intended for cultivation in its 20,000 square foot, EU-GMP compliant facility in Princeton, British Columbia.

The Company's acquisition includes 24 psychedelic and nine functional strains, giving it one of the largest genetic banks in the sector. Formulated psychedelic strains will be made available to licensed researchers, Canada's Special Access Program (SAP), as well as being utilized for on-site research in Optimi's recently expanded analytical laboratory, while the functional strains will be optimized for the Company's growing whole body, natural supplement brand, Optimi Life.

Last week, Optimi applauded Health Canada's Notice to Stakeholders which specified the "importance of drug quality and Good Manufacturing Practices (GMP)" in supplying psilocybin to clinical trials and the SAP. As a leading cultivator of natural EU-GMP psilocybin,



optimi™ CSE: OPTI | OTCQX: OPTHF | FRA: 8BN

SUBSCRIBE FOR UPDATES

MENU



"We want to be in a place where we can facilitate as broad a spectrum of research as possible," said Optimi Health Chief Science Officer Justin Kirkland. "From the data available so far, we can say with relative certainty that psychedelic research and any novel psilocybin-assisted therapies that may result are not going to be a one-size-fits-all process. It is entirely possible that certain strains of mushrooms with varying chemical compositions and potency will lead to varying degrees of efficacy across a wide array of mental health indications when paired with the appropriate therapeutic protocols."

By collating information from clinical trials, using mushrooms from both its own supply and other sources throughout the sector, Optimi is committed to working within the regulatory approval processes necessary to ensure access to those in need.

Optimi CEO Bill Ciprick expanded on the shared scientific and commercial advantages provided by the company's comprehensive knowledge of psilocybin genetics.

"In conjunction with the recent completion of our analytical laboratory, this acquisition is intended to position Optimi as the leading supplier of naturally-sourced psilocybin to the burgeoning psychedelic industry," said Ciprick. "Optimi's strategic year of commercialization is based around our growing capacity to supply and analyze as many strains of GMP psilocybin as may be necessary to ensure the success of the hundreds of clinical trials and drug discovery efforts currently underway, underpinning both the future of psychedelic science and the commercial viability of the space as a whole," Ciprick concluded.

GRAND OPENING

On May 27th, the Company will be welcoming guests and dignitaries from the psychedelic business space, the medical and public health fields, local and national politics, and the Indigenous community for a grand opening event and facility tour to inaugurate its Princeton, BC facility. For those interested in attending in-person or via livestream should contact event organizer, Michael Kydd, at info@kyddergroup.com.

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi Health is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets. Built with the purpose to produce scalable, natural mushroom formulations for transformational human experiences, the Company's goal is to be the number one trusted.



optimi™ CSE: OPTI | OTCQX: OPTHF | FRA: 8BN

SUBSCRIBE FOR UPDATES

MENU



governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations

Email: investors@optimihealth.ca

Phone: +1 (902) 880 6121 Web: https://optimihealth.ca

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements") that relate to Optimi's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward-looking statements pertaining to activities proposed to be conducted under the Company's dealer's license and associated business related to Psilocybin and Psilocin and Optimi's plans, focus and objectives.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited





SUBSCRIBE FOR UPDATES

VENU



Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.







optimi[™] CSE: OPTI | OTCQX: OPTHF | FRA: 8BN

SUBSCRIBE FOR UPDATES





• UNCATEGORIZED

U.K. MEMBER OF PARLIAMENT CRISPIN BLUNT TO INAUGURATE PSILOCYBIN CULTIVATION FACILITY AT OPTIMI HEALTH GRAND OPENING

19 MAY 2022

OPTIMI HEALTH ACQUIRES EXTENSIVE CATALOG OF PSYCHEDELIC AND FUNCTIONAL MUSHROOM GENETICS

17 MAY 2022

OPTIMI HEALTH COMPLETES EXPANSION OF ON-SITE ANALYTICAL LABORATORY

11 MAY 2022

OPTIMI HEALTH APPLAUDS HEALTH CANADA'S POSITION ON DRUG QUALITY AND GOODS AND MANUFACTURING PRACTICES (GMP) FOR **PSILOCYBIN**

9 MAY 2022

OPTIMI HEALTH GRANTED AMENDMENT TO CONTROLLED SUBSTANCES DEALER'S LICENCE

4 MAY 2022

FOUNDERS MESSAGE: MAY 2, 2022

2 MAY 2022



SUBSCRIBE FOR UPDATES





SUBSCRIBE TO OUR MAILING LIST

Sign up to receive our latest news and updates!

Name *	
Email *	
☐ I consent to receiving future communications from Optimi Health. *	
SUBMIT	

CSE: OPTI | OTCQX: OPTHF | FRA: 8BN



SUBSCRIBE FOR UPDATES

VENU

TEAM

ADVISORS

STRATEGY

FUTURE

OPERATIONS

FARMS

LABS

PRODUCTS

INVESTORS

NEWS

CONTACT

© Copyright - 2022 Optimi Health. All rights reserved.

Privacy Policy

Disclaimer